Entrada Therapeutics (TRDA) FCF Margin: 2023-2025
Historic FCF Margin for Entrada Therapeutics (TRDA) over the last 3 years, with Sep 2025 value amounting to -1,743.62%.
- Entrada Therapeutics' FCF Margin fell 161636.00% to -1,743.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -210.98%, marking a year-over-year decrease of 20287.00%. This contributed to the annual value of -21.21% for FY2024, which is 12523.00% down from last year.
- As of Q3 2025, Entrada Therapeutics' FCF Margin stood at -1,743.62%, which was down 14.23% from -1,526.36% recorded in Q2 2025.
- In the past 5 years, Entrada Therapeutics' FCF Margin registered a high of 798.62% during Q1 2023, and its lowest value of -1,743.62% during Q3 2025.
- For the 3-year period, Entrada Therapeutics' FCF Margin averaged around -286.73%, with its median value being -86.21% (2024).
- As far as peak fluctuations go, Entrada Therapeutics' FCF Margin spiked by 24,246bps in 2024, and later crashed by 161,636bps in 2025.
- Quarterly analysis of 3 years shows Entrada Therapeutics' FCF Margin stood at -11.92% in 2023, then plummeted by 7,429bps to -86.21% in 2024, then plummeted by 161,636bps to -1,743.62% in 2025.
- Its last three reported values are -1,743.62% in Q3 2025, -1,526.36% for Q2 2025, and -192.87% during Q1 2025.